Literature DB >> 1026810

Side effects of clofazimine therapy.

G Ramu, G G Iyer.   

Abstract

84 patients of leprosy including 15 female patients were treated with Clofzimine on a predetermined dosage regimen. 76 of these were cases of recurrent lepra reaction; 4 cases of proven DDS resistance, 3 of these being complicated by lepra reaction; and 4 were cases of reactional state in Borderline leprosy near the lepromatous end of the spectrum. The common side effect in all cases consisted of red and dark skin pigmentation of varying intensity occuring within 10 weeks of the commencement of therapy. The intensity of the colour was proportionate to the density of the infiltration. Ichthyosis occurred in 66.6% of cases. While the pigmentation was accepted by the patients in general, 10% of the patients considered ichthyosis as stigmatising. While side effects like anorexia, diarrhoea, enlargement of lymph glands and liver, corneal xerosis and loss of weight were self correcting, severe gastrointestinal manifestation, i.e. severe abdominal pain, vomiting and diarrhoea were observed in 9 patients, 5 of whom were females. Mortality was high in the females. On an incidental finding the Isonizair reduced the severity of the manifestations, it was supplemented in 10 cases on Clofazimine therapy and was found to minimise the side effects and the pigmentation due to Clofazimine. Hydration therapy for the ichthyosis and instillation of normal saline and liquid paraffin for corneal xerosis were found to be very useful.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1026810

Source DB:  PubMed          Journal:  Lepr India        ISSN: 0024-1024


  7 in total

1.  Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids.

Authors:  B Auclair; D E Nix; R D Adam; G T James; C A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  Safety and tolerability profile of second-line anti-tuberculosis medications.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

Review 3.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

4.  Abnormalities in stratum corneum function in patients recovered from leprosy.

Authors:  S-P Song; C-Z Lv; K R Feingold; Q-N Hou; Z-Y Li; C-Y Guo; P M Elias; M Q Man
Journal:  Skin Pharmacol Physiol       Date:  2009-01-09       Impact factor: 3.479

Review 5.  Extensively Drug-Resistant Tuberculosis: Report and Literature Review on Two Cases Requiring Prolonged Treatment.

Authors:  Martha Matos-Tocasca; Gabriel De la Cruz-Ku; Erick Auccacusi; Diego Fernandez-Salas; Tatiana García-Ahuanari; Bryan Valcarcel-Valdivia
Journal:  Am J Case Rep       Date:  2016-11-03

Review 6.  Tuberculosis: Past, present and future of the treatment and drug discovery research.

Authors:  Ameya D Bendre; Peter J Peters; Janesh Kumar
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-05-27

7.  Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes.

Authors:  Yunzhao R Ren; Fan Pan; Suhel Parvez; Andrea Fleig; Curtis R Chong; Jing Xu; Yongjun Dang; Jin Zhang; Hongsi Jiang; Reinhold Penner; Jun O Liu
Journal:  PLoS One       Date:  2008-12-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.